Emergent BioSolutions, Inc. EBS 深 滬
等待開盤 10-24 09:30:00 美东时间
9.66
+0.230
+2.44%
華盛通- 最 高9.745
- 今 開9.55
- 成交量 62.21万股
- 最 低 9.43
- 昨 收 9.43
- 總市值 5.15亿
- 52周最高 12.73
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.02
- 委 比 77.78%
- 總股本 5335.11万
- 歷史最高 137.61
- 量 比 0.82
- 振 幅 3.34%
- 歷史最低 1.42
- 每 手 1
- 風險率 1.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多S&P Global and CME Group Complete Sale of OSTTRA to KKR
NEW YORK, Oct. 10, 2025 /PRNewswire/ -- S&P Global (NYSE: SPGI) and CME Group today announced that they have completed the sale of OSTTRA to KKR, a leading global investment firm. The terms ...
10-10 19:00
Oracle rises even as Google says e-business cybersecurity incident is widespread
Oracle (NYSE:ORCL) rose than 2% on Thursday, even as Google's (NASDAQ:GOOG) (NASDAQ:GOOG) Mandiant cybersecurity unit said the cybersecurity incident into Oracle's e-business unit is widespread. “Our ...
10-09 23:10
CME Group Announces That Its Cryptocurrency Futures And Options Will Be Available To Trade 24 Hours A Day, Seven Days A Week Beginning In Early 2026, Pending Regulatory Review
CHICAGO, Oct. 2, 2025 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that its cryptocurrency futures and options will be available to trade 24 hours a day, seven days a week
10-02 22:07
Envista Schedules Third Quarter 2025 Earnings Call
BREA, Calif., Sept. 30, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its third quarter 2025 on Thursday, October 30, 2025. Env...
10-01 04:15
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
Emergent BioSolutions renews commitment to combating opioid crisis through awareness, education, and increased access to naloxone products like NARCAN® and KLOXXADO®. The company highlights September observances such as National Preparedness Month, Recovery Month, and Opioid Awareness Day. Emergent partners with organizations like the National Safety Council and Penington Institute to promote workplace safety and community education. The company ...
09-24 20:05
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
Emergent BioSolutions has secured a $29 million international government contract for medical countermeasures against threats like smallpox, anthrax, and botulism. This is the second procurement this year, with $26 million set to be received in 2025. The orders reflect increasing global defense preparedness and align with NATO's commitment to raising defense spending, supporting Emergent's international expansion and multi-year growth plan.
09-19 12:34
Emergent BioSolutions secures $17M contract modification for oral suspension TEMBEXA
Emergent BioSolutions (NYSE:EBS) announced on Monday it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority, part of the Administration for...
09-15 20:54
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
Emergent BioSolutions has received a $17 million contract modification from BARDA to supply TEMBEXA® oral suspension, following FDA approval of its manufacturing scale-up. TEMBEXA® is approved for treating smallpox in adults and pediatric patients, including neonates, with the oral suspension providing an alternative for those unable to swallow. The contract modification builds on previously announced options under a 10-year agreement, supporting...
09-15 12:35
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
GAITHERSBURG, Md. – Emergent BioSolutions announced a $56 million contract modification to supply ACAM2000® (Smallpox and Mpox Vaccine) to the U.S. government, with deliveries beginning this month. This brings total projected sales to over $120 million. ACAM2000® is licensed for immunization against smallpox and mpox in high-risk individuals. Paul Williams, senior vice president at Emergent, highlighted the company's commitment to supporting publ...
09-09 11:30
Emergent BioSolutions Secures $30M BARDA Contract Extension
Emergent Biosolutions ( ($EBS) ) has issued an announcement. On August 29, 2025...
09-06 05:49
